Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: Lack of interaction in uremic sera due to the presence of endogenous factors

Therapeutic Drug Monitoring

Volumn 18, Issue 6, 1996, Pages 654-659

  Dasgupta, Amitava ^a,b   Emerson, Lyska ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

Author keywords

Fenoprofen; Mefenamic acid; Uremia; Valproic acid

Indexed keywords

ACTIVATED CARBON; ALBUMIN; ANTIINFLAMMATORY AGENT; BILIRUBIN; CREATININE; FENOPROFEN; HIPPURIC ACID; INDICAN; LIVER ENZYME; MEFENAMIC ACID; UREA; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; HUMAN; PRIORITY JOURNAL; UREMIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; DRUG INTERACTIONS; FENOPROFEN; HUMANS; MEFENAMIC ACID; PROTEIN BINDING; UREMIA; VALPROIC ACID;

EID: 0029809522     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199612000-00005     Document Type: Article

References (17)

1. Bruni J, Albright P. Valproic acid therapy for complex partial seizures: its efficacy and toxic effects. Arch Neurol 1983; 40:135-7.
2. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a five year follow up study on 100 children. Acta Neurol Scand 1982;65:504-23.
3. Scheyer RD, Cramer JA, Toftness BR, Hochholer JM, Mattson RH. In vitro determination of valproate binding constants during sole and multidrug therapy. Ther Drug Monit 1990;12:117-23.
4. Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of antiepileptics and free fatty acids. Epilepsia 1979;20:85-90.
5. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 1977; 21:736-43.
6. Perucca E. Free level monitoring of antiepileptic drugs: clinical usefulness and case studies. Clin Pharmokinetic 1984;9(Suppl):71-8.
7. Takeda A, Gotto H, Amano Y, Kukino K. A study on serum and CSF levels of sodium valproate, a new antiepileptic drug. Brain Dev 1976;8:401-8.
8. Bruni J, Wang LH, Marbury TC, Lee CS, Wilder BJ. Protein binding of valproic acid in uremic patients. Neurology 1980; 30:557-9.
9. Sjoholm I, Kober A, Odar-Cederlof I, Borga A. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976; 25:1205-13.
10. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 1982;31:642-9.
11. Chen R. Removal of fatty acid from serum by charcoal treatment. J Biol Chem 1967;242:178-81.
12. Craig WA, Evenson MA, Sarver KP, Wagnild JP. Correction of protein binding defect of uremic serum by charcoal treatment. J Lab Clin Med 1976;87:637-47.
13. Depner TA, Gulyassy PF. Plasma protein binding in uremia: extraction and characterization of an inhibitor. Kidney Int 1980;18:86-94.
14. Dasgupta A, Jacques M. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera: role of uremic compounds. Am J Clin Pathol 1994;101:349-53.
15. Dasgupta A, Abu-Alfa A. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis: role of uremic compounds. Am J Clin Pathol 1992;98:19-25.
16. Vanholder R, DeSmet R, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992;38:1429-36.
17. Dasgupta A, Malik S. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding sites: absence of midmolecular uremic toxins. Am J Nephrol 1994;14:162-8.